Premenstrual syndrome and premenstrual dysphoric disorder in adolescents

Current Opinion in Obstetrics and Gynecology

Volumn 20, Issue 5, 2008, Pages 455-463

  Rapkin, Andrea J ^a   Mikacich, Judith A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Adolescents; Premenstrual dysphoric disorder; Premenstrual syndrome; Teens

Indexed keywords

AMFEBUTAMONE; CALCIUM CARBONATE; CITALOPRAM; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL; ETHINYLESTRADIOL; FLUOXETINE; GESTAGEN; GONADORELIN AGONIST; MAPROTILINE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SEX HORMONE; SPIRONOLACTONE; STEROID HORMONE; VENLAFAXINE; VITEX AGNUS CASTUS EXTRACT;

ACNE; ADOLESCENT; AEROBIC EXERCISE; ANEMIA; ANXIETY; BLOATING; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; COMORBIDITY; DEPRESSION; DIET THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DYSMENORRHEA; FUNCTIONAL DISEASE; GASTROINTESTINAL IRRITATION; HEALTH EDUCATION; HUMAN; INSOMNIA; IRRITABILITY; LIFESTYLE MODIFICATION; LIMB SWELLING; LOW DRUG DOSE; MASTALGIA; MENTAL DISEASE; MENTAL STRESS; MOOD DISORDER; MULTIPLE CYCLE TREATMENT; ONSET AGE; OVARY; PELVIS PAIN SYNDROME; PHOTOTHERAPY; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; REVIEW; SEX HORMONE DETERMINATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SWEATING; UNSPECIFIED SIDE EFFECT; VITAMIN INTAKE;

ADOLESCENT; ADULT; ANXIETY DISORDERS; COMORBIDITY; FEMALE; HUMANS; MENSTRUATION; MOOD DISORDERS; OVARY; PREMENSTRUAL SYNDROME; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN; STEROIDS; YOUNG ADULT;

EID: 55349118858     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e3283094b79     Document Type: Review

References (101)

1. Freeman E. The clinical presentation and course of premenstrual symptoms. In: O'Brien PMS, Rapkin AJ, Schmidt PJ, editors. The premenstrual syndromes: PMS and PMDD. Boca Raton, FL: Taylor & Francis; 2007. pp. 55-61.
2. Johnson SR, McChesney C, Bean JA. Epidemiology of premenstrual symptoms in a nonclinical sample. I. Prevalence, natural history and help-seeking behavior. J Reprod Med 1988; 33:340-346.
3. Steiner M, Macdougall M, Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Arch Womens Ment Health 2003; 6:203-209.
4. Halbreich U, Backstrom T, Eriksson E, et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol Endocrinol 2007; 23:123-130.
5. Rapkin AJ, Winer SA. The pharmacologic management of premenstrual dysphoric disorder. Expert Opin Pharmacother 2008; 9:429-445.
6. Keye W. Premenstrual syndrome. In: Proceedings of a conference on PMS and related biobehavioral disorders. Provo, UT: BYU Division of Conferences; 1983. pp. 1-10.
7. Robinson RL, Swindle RW. Premenstrual symptom severity: impact on social functioning and treatment-seeking behaviors. J Womens Health Gend Based Med 2000; 9:757-768.
8. Montera P, Bernis C, Loukid M, et al. Characteristics of menstrual cycles in Moroccan girls: prevalence of dysfunctions and associated behaviours. Ann Hum Biol 1999; 26:243-249.
9. Wilson C, Emans SJ, Mansfield J, et al. The relationships of calculated percentage body fat, sports participation, age, and place of residence on menstrual patterns in healthy adolescent girls at an independent New England high school. J Adolesc Healthcare 1984; 5:248-253.
10. Wilson CA, Keye WR Jr. A survey of adolescent dysmenorrhea and premenstrual symptom frequency. A model program for prevention, detection, and treatment. J Adolesc Healthcare 1989; 10:317-322.
11. Shye D, Jaffe B. Prevalence and correlates of perimenstrual symptoms: a study of Israeli teenage girls. J Adolesc Health 1991; 12:217-224.
12. Wittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002; 32:119-132.
13. Rojnic Kuzman M, Hotujac L. Premenstrual dysphoric disorder - a neglected diagnosis? Preliminary study on a sample of Croatian students. Coll Antropol 2007; 31:131-137.
14. Yonkers KA, White K. Premenstrual exacerbation of depression: one process or two? J Clin Psychiatry 1992; 53:289-292.
15. Yonkers KA. The association between premenstrual dysphoric disorder and other mood disorders. J Clin Psychiatry 1997; 58 (Suppl 15):19-25.
16. Perry BL, Miles D, Burruss K, Svikis DS. Premenstrual symptomatology and alcohol consumption in college women. J Stud Alcohol 2004; 65:464-468.
17. Sein Anand J, Chodorowski Z, Ciechanowicz R, et al. The relationship between suicidal attempts and menstrual cycle in women. Przegl Lek 2005; 62:431-433.
18. Lee DO. Menstrually related self-injurious behavior in adolescents with autism. J Am Acad Child Adolesc Psychiatry 2004; 43:1193.
19. American College of Obstetricians and Gynecologists. Premenstrual syndrome. ACOG Practice Bulletin 2000; 15.
20. American Psychiatric Association. Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000. xxxvii + 943 pp.
21. Derman O, Kanbur NO, Tokur TE, Kutluk T. Premenstrual syndrome and associated symptoms in adolescent girls. Eur J Obstet Gynecol Reprod Biol 2004; 116:201-206.
22. Cleckner-Smith CS, Doughty AS, Grossman JA. Premenstrual symptoms. Prevalence and severity in an adolescent sample. J Adolesc Health 1998; 22:403-408.
23. Vichnin M, Freeman EW, Lin H, et al. Premenstrual syndrome (PMS) in adolescents: severity and impairment. J Pediatr Adolesc Gynecol 2006; 19:397-402.
24. Lee LK, Chen PC, Lee KK, Kaur J. Menstruation among adolescent girls in Malaysia: a cross-sectional school survey. Singapore Med J 2006; 47:869-874.
25. Hammarback S, Damber JE, Backstrom T. Relationship between symptom severity and hormone changes in women with premenstrual syndrome. J Clin Endocrinol Metab 1989; 68:125-130.
26. Sulak PJ. Continuous oral contraception: changing times. Best Pract Res Clin Obstet Gynaecol 2008; 22:355-374.
27. Freeman EW, Schweizer E, Rickels K. Personality factors in women with premenstrual syndrome. Psychosom Med 1995; 57:453-459.
28. Pearlstein TB, Frank E, Rivera-Tovar A, et al. Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder. J Affect Disord 1990; 20:129-134.
29. Labad J, Menchon JM, Alonso P, et al. Female reproductive cycle and obsessive-compulsive disorder. J Clin Psychiatry 2005; 66:428-435; quiz 546.
30. Portella AT, Haaga DA, Rohan KJ. The association between seasonal and premenstrual symptoms is continuous and is not fully accounted for by depressive symptoms. J Nerv Ment Dis 2006; 194:833-837.
31. Wilson CA, Turner CW, Keye WR Jr. Firstborn adolescent daughters and mothers with and without premenstrual syndrome: a comparison. J Adolesc Health 1991; 12:130-137.
32. Perkonigg A, Yorkers KA, Pfister H, et al. Risk factors for premenstrual dysphoric disorder in a community sample of young women: the role of traumatic events and posttraumatic stress disorder. J Clin Psychiatry 2004; 65:1314-1322.
33. Koci A, Strickland O. Relationship of adolescent physical and sexual abuse to perimenstrual symptoms (PMS) in adulthood. Issues Ment Health Nurs 2007; 28:75-87.
34. Masho SW, Adera T, South-Paul J. Obesity as a risk factor for premenstrual syndrome. J Psychosom Obstet Gynaecol 2005; 26:33-39.
35. Treolar S, Heath A, Martin N. Genetic and environmental influences on premenstrual symptoms in an Australian twin sample. Psychol Med 2002; 32:25-38.
36. Condon JT. The premenstrual syndrome: a twin study. Br J Psychiatry 1993; 162:481-486.
37. Rubinow DR, Hoban MC, Graver GN, et al. Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects. Am J Obstet Gynecol 1988; 158:5-11.
38. Schmidt PJ, Nieman LK, Danaceau MA, et al. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 1998; 338:209-216.
39. Rapkin A. Progesterone, GABA and mood disorders in women. Arch Womens Ment Health 1999; 2:97-105.
40. Rapkin AJ, Kuo J. Neurotransmitter physiology: the basics for understanding premenstrual syndrome. In: O'Brien PMS, Rapkin AJ, Schmidt PJ, editors. The premenstrual syndromes: PMS and PMDD. Boca Raton, FL: Taylor & Francis; 2007. pp. 69-81.
41. Bethea CL Regulation of progestin receptors in raphe neurons of steroid-treated monkeys. Neuroendocrinology 1994; 60:50-61.
42. Graeff FG, Guimaraes FS, De Andrade TG, Deakin JF. Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav 1996; 54:129-141.
43. Jenike MA, Rauch SL, Cummings JL, et al. Recent developments in neuro-biology of obsessive-compulsive disorder. J Clin Psychiatry 1996; 57:492-503.
44. Charney DS. Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Psychiatr Scand Suppl 2003:38-50.
45. Sundstrom Poromaa I, Smith S, Gulinello M. GABA receptors, progesterone and premenstrual dysphoric disorder. Arch Womens Ment Health 2003; 6:23-41.
46. Girdler SS, Straneva PA, Light KC, et al. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol Psychiatry 2001; 49:788-797.
47. Smith SS, Gong QH, Hsu FC, et al. GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid. Nature 1998; 392:926-930.
48. Sundstrom I, Andersson A, Nyberg S, et al. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinology 1998; 67:126-138.
49. Rapkin AJ, Morgan M, Goldman L, et al. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 1997; 90:709-714.
50. Monteleone P, Luisi S, Tonetti A, et al. Allopregnanolone concentrations and premenstrual syndrome. Eur J Endocrinol 2000; 142:269-273.
51. Thys-Jacobs S, McMahon D, Bilezikian JP. Cyclical changes in calcium metabolism across the menstrual cycle in women with premenstrual dysphoric disorder. J Clin Endocrinol Metab 2007; 92:2952-2959.
52. Houston AM, Abraham A, Huang Z, D'Angelo LJ. Knowledge, attitudes, and consequences of menstrual health in urban adolescent females. J Pediatr Adolesc Gynecol 2006; 19:271-275.
53. Rapkin AJ, Mikacich JA. Premenstrual syndrome in adolescents: diagnosis and treatment. Pediatr Endocrinol Rev 2006; 3 (Suppl 1):132-137.
54. Rapkin AJ, Mikacich J. Clinical evaluation and management. In: O'Brien PMS, Rapkin AJ, Schmidt PJ, editors. The premenstrual syndromes: PMS and PMDD. Boca Raton, FL: Taylor & Francis; 2007. pp. 149-159.
55. Chau JP, Chang AM. Effects of an educational programme on adolescents with premenstrual syndrome. Health Educ Res 1999; 14:817-830.
56. Hunter MS, Ussher JM, Browne SJ, et al. A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol 2002; 23:193-199.
57. Steege JF, Blumenthal JA. The effects of aerobic exercise on premenstrual symptoms in middle-aged women: a preliminary study. J Psychosom Res 1993; 37:127-133.
58. Thys-Jacobs S, Starkey P, Bernstein D, Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol 1998; 179: 444-452.
59. Bertone-Johnson ER, Hankinson SE, Bendich A, et al. Calcium and vitamin D intake and risk of incident premenstrual syndrome. Arch Intern Med 2005; 165:1246-1252.
60. Joffee H, Cohen LS, Harlow BL. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am J Obstet Gynecol 2003; 189:1523-1530.
61. Sulak PJ, Scow RD, Preece C. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000; 95:261-266.
62. Lopez LM, Kaptein A, Heimerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2008:CD006586. This is an important summary of oral contraceptives containing drospirenone for PMS.
63. Sullivan H, Furniss H, Spona J, Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril 1999; 72:115-120.
64. Yonkers KA, Brown C, Pearlstein TB, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005; 106:492-501.
65. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005; 72:414-421.
66. YAZ (drospirenone and ethinyl estradiol) [prescribing information]. Montville, NJ: Berlex, Inc.; October 2006.
67. Muhn P, Krattenmacher R, Beier S, et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception 1995; 51:99-110.
68. Greco T, Graham CA, Bancroft J, et al. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol. Contraception 2007; 76:8-17.
69. Steiner M, Steinberg S, Steward D, et al. Fluoxetine in the treatment of premenstrual dysphoria. N Engl J Med 1995; 332:1529-1534.
70. Freeman EW, Rickels K, Arredondo F, et al. Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. J Clin Psychopharmacol 1999; 19:3-8.
71. Halbreich U, Smoller JW. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 1997; 58:399-402.
72. Steiner M, Hirschberg AL, Bergeron R, et al. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. Am J Obstet Gynecol 2005; 193:352-360.
73. Wikander I, Sundblad C, Andersch B, et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol 1998; 18:390-398.
74. Freeman EW, Rickels K, Yonkers KA, et al. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol 2001; 98:737-744.
75. Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. JAMA 1997; 278:983-988.
76. Cohen LS, Soares CN, Yonkers KA, et al. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial. Psychosom Med 2004; 66:707-713.
77. Halbreich U, Bergeron R, Yonkers KA, et al. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 2002; 100:1219-1229.
78. Kornstein SG, Pearlstein TB, Fayyad R, et al. Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: efficacy of 3 dosing strategies. J Clin Psychiatry 2006; 67:1624-1632.
79. Steiner M, Brown E, Trzepacz P, et al. Fluoxetine improves functional work capacity in women with premenstrual dysphoric disorder. Arch Womens Ment Health 2003; 6:71-77.
80. Pearlstein T, Joliat MJ, Brown EB, Miner CM. Recurrence of symptoms of premenstrual dysphoric disorder after the cessation of luteal-phase fluoxetine treatment Am J Obstet Gynecol 2003; 188:887-895.
81. Pearlstein TB, Stone AB, Lund SA, et al. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 1997; 17:261-266.
82. Doggrell SA. Fluoxetine - do the benefits outweigh the risks in adolescent major depression? Expert Opin Pharmacother 2005; 6:147-150.
83. Hetrick S, Merry S, McKenzie J, et al. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database Syst Rev 2007:CD004851.
84. Nur MM, Romano ME, Siqueira LM. Premenstrual dysphoric disorder in an adolescent female. J Pediatr Adolesc Gynecol 2007; 20:201-204. A case report of an adolescent with PMDD treated successfully with luteal phase dosing of fluoxetine 20 mg.
85. Silber TJ, Valadez-Meltzer A. Premenstrual dysphoric disorder in adolescents: case reports of treatment with fluoxetine and review of the literature. J Adolesc Health 2005; 37:518-525.
86. US Food and Drug Administration. Antidepressant use in children, adolescents, and adults. Center for Drug Evaluation and Research; May 12, 2008. http://www.fda.gov/cder/.
87. Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry 2006; 163:1898-1904.
88. Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007; 164:1356-1363.
89. Jackson B, Lurie S. Adolescent depression: challenges and opportunities: a review and current recommendations for clinical practice. Adv Pediatr 2006; 53:111-163.
90. Scahill L, Hamrin V, Pachler ME. The use of selective serotonin reuptake inhibitors in children and adolescents with major depression. J Child Adolesc Psychiatr Nurs 2005; 18:86-89.
91. Rowe L, Tonge B, Melvin G. When should GPs prescribe SSRIs for adolescent depression? Aust Fam Physician 2004; 33:1005-1008.
92. Ginsburg KA, Dinsay R. Premenstrual syndrome. In: Ransom SB, editor. Practical strategies in obstetrics and gynecology. Philadelphia: W.B. Saunders Company; 2000. ; p. 10.
93. Vellacott ID, Shroff NE, Pearce MY, et al. A double-blind, placebo-controlled evaluation of spironolactone in the premenstrual syndrome. Curr Med Res Opin 1987; 10:450-456.
94. Wang M, Hammarback S, Lindhe BA, Backstrom T. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet Gynecol Scand 1995; 74:803-808.
95. Muse KN, Cetel NS, Futterman LA, Yen SC. The premenstrual syndrome. Effects of 'medical ovariectomy'. N Engl J Med 1984; 311:1345-1349.
96. Mortola JF, Girton L, Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. J Clin Endocrinol Metab 1991; 72:252A-252F.
97. Mezrow G, Shoupe D, Spicer D, et al. Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. Fertil Steril 1994; 62:932-937.
98. Lam RW, Carter D, Misri S, et al. A controlled study of light therapy in women with late luteal phase dysphoric disorder. Psychiatry Res 1999; 86:185-192.
99. Girman A, Lee R, Kligler B. An integrative medicine approach to premenstrual syndrome. Am J Obstet Gynecol 2003; 188:856-365.
100. Wuttke W, Jarry H, Christoffel V, et al. Chaste tree (Vitex agnus castus) - pharmacology and clinical indications. Phytomedicine 2003; 10:348-357.
101. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. Br Med J 2001; 322:134-137.